Uporedite metode
Pregledajte izabrane metode jednu pored druge; redovi koji se razlikuju su istaknuti.
| Indeks aktivnosti kolitisa (SCCAI)× | Kratki upitnik o zapaljenskoj bolesti creva× | |
|---|---|---|
| Oblast | Gastroenterologija | Gastroenterologija |
| Porodica | Process / pipeline | Process / pipeline |
| Godina nastanka≠ | 1998 | 2004 |
| Tvorac≠ | Walmsley, R. S., Ayres, R. C., Pounder, R. E., and Allan, R. N. | Guyonnet, D., Chassany, O., Ducroc, R., et al. |
| Tip≠ | Clinician-rated | Self-report |
| Temeljni izvor≠ | Walmsley, R. S., Ayres, R. C., Pounder, R. E., & Allan, R. N. (1998). A simple clinical colitis activity index. Gut, 43(1), 29–32. DOI ↗ | Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465. link ↗ |
| Drugi nazivi≠ | SCCAI | IBDQ-32, Short IBDQ |
| Srodne | 4 | 4 |
| Sažetak≠ | The Simple Clinical Colitis Activity Index (SCCAI) is a practical, bedside tool for assessing disease activity in ulcerative colitis and colonic Crohn's disease. Published in 1998 by Walmsley and colleagues, the SCCAI condenses disease assessment into six items that can be administered in a office visit without laboratory or endoscopic data. It provides rapid, reproducible quantification of disease severity and is ideal for frequent monitoring in routine clinical practice. | The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice. |
| ScholarGateSkup podataka ↗ |
|
|